ArticleCarcinogenesis2008
Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer.
Article in Carcinogenesis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.Breast cancer research : BCR · 2020Pooled it
- Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.Breast cancer research : BCR · 2015Pooled it
- Paralogous HOX13 Genes in Human Cancers.Cancers · 2019Review
- The function of homeobox genes and lncRNAs in cancer.Oncology letters · 2016Article
- DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.Clinical epigenetics · 2015Article
- Article
- Estrogen receptor α-coupled Bmi1 regulation pathway in breast cancer and its clinical implications.BMC cancer · 2014Article
- Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis.Breast cancer research : BCR · 2014Article
- Computational prognostic indicators for breast cancer.Cancer management and research · 2014Review
- Analysis of HOX gene expression patterns in human breast cancer.Molecular biotechnology · 2014Article
- Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.Molecular endocrinology (Baltimore, Md.) · 2012Article
- Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis.Breast cancer research : BCR · 2012Review
- Increased HOX C13 expression in metastatic melanoma progression.Journal of translational medicine · 2012Article
- Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.Cancer biology & therapy · 2011Article
- Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.Genome research · 2010Article
- HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.Molecular cancer · 2010Article
- HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors.PloS one · 2010Article
- Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.Journal of mammary gland biology and neoplasia · 2010Review
- Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.Breast cancer research : BCR · 2010Article
- DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.Genes, chromosomes & cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Several studies have reported that a high expression ratio of HOXB13 to IL17BR predicts tumor recurrence in node-negative, estrogen receptor (ER) alpha-positive breast cancer patients treated with tamoxifen. The molecular mechanisms underlying this dysregulation of gene expression remain to be explored. Our epigenetic analysis has found that increased promoter methylation of one of these genes, HOXB13, correlate with the decreased expression of its transcript in breast cancer cell lines (P < 0.005). Transcriptional silencing of this gene can be reversed by a demethylation treatment. HOXB13 is suppressed by the activation of estrogen signaling in ERalpha-positive breast cancer cells. However, treatment with 4-hydroxytamoxifen (4-OHT), an antiestrogen, abrogates the ERalpha-mediated suppression in cancer cells. The notion that this transcriptional induction of HOXB13 occurs in vitro with simultaneous exposure to both estrogen and 4-OHT may provide a biological explanation for its aberrant expression in many node-negative patients undergoing tamoxifen therapy. Interestingly, promoter hypermethylation of HOXB13 is more frequently observed in ERalpha-positive patients with increased lymph node metastasis (P = 0.031) and large tumor sizes (>5 cm) (P = 0.008). In addition, this aberrant epigenetic event is associated with shorter disease-free survival (P = 0.029) in cancer patients. These results suggest that hypermethylation of HOXB13 is a late event of breast tumorigenesis and a poor prognostic indicator of node-positive cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.